Patents by Inventor Robert G.E. Holgate

Robert G.E. Holgate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
    Patent number: 11723951
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: August 15, 2023
    Assignee: Amyl Therapeutics SRL
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE LACKING A GLYCOSYLATION SIGNAL
    Publication number: 20210015895
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: June 18, 2020
    Publication date: January 21, 2021
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
    Patent number: 10722551
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 28, 2020
    Assignee: Proclara Biosciences, Inc.
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE LACKING A GLYCOSYLATION SIGNAL
    Publication number: 20180207231
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: December 2, 2015
    Publication date: July 26, 2018
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G.E. Holgate, Timothy D. Jones